The Filing Desk

Chemours vs Orion

Chemours CC · Orion OEC · Diversified Chemicals

Chemours reported revenue of $5.8 billion in fiscal 2025, 3.2 times Orion's $1.8 billion in fiscal 2025. Chemours' revenue grew 0.5% in its latest year, and Orion's fell 3.8%. Free cash flow was $51 million at Chemours and $55 million at Orion.

Side by side

ChemoursOrion
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$5.8B$1.8B
Revenue growth0.5%−3.8%
Revenue growth a year, last 5 years3.2%9.7%
Gross margin15.5%19.9%
Operating margin—1.5%
Net margin−6.7%−3.9%
Free cash flow$51M$55M
Free cash flow margin0.9%3.0%
Return on capital−0.2%1.3%
Net debt to EBITDA10.6x8.1x
Dividends and buybacks$78M$30M
Change in diluted share count0.0%−3.5%
Last close$13.29$3.99
P/E at the last close——
Insider trades, last 12 monthsbought $488,650, sold $0—
Piotroski F-score4 of 93 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ChemoursOrion
Operating margin
Percent of revenue
ChemoursOrion
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ChemoursOrion

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Chemours and Orion pages.